4-[2-(1-羟基-乙基)-吡啶-4-基]-哌嗪-1-磺酸二甲基酰胺 | 654071-69-9

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 二嗪烷类
• 中文名称: 4-[2-(1-羟基-乙基)-吡啶-4-基]-哌嗪-1-磺酸二甲基酰胺
• 英文名称: 4-[2-(1-Hydroxy-ethyl)-pyridin-4-yl]-piperazine-1-sulfonic acid dimethylamide
• CAS: 654071-69-9
• 化学式: C₁₃H₂₂N₄O₃S
• 分子量: 314.409
• InChiKey: BVBONSQQVFMUOL-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  0.06
• 重原子数：
  21.0
• 可旋转键数：
  4.0
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.62
• 拓扑面积：
  76.98
• 氢给体数：
  1.0
• 氢受体数：
  5.0

反应信息

• 作为反应物：
  描述：

  4-[2-(1-羟基-乙基)-吡啶-4-基]-哌嗪-1-磺酸二甲基酰胺 在 sodium hydroxide 、 Lipase P₃₀ 作用下， 以 1,4-二氧六环 、 甲醇 为溶剂， 反应 97.0h， 生成
  参考文献：
  名称：

  Design and synthesis of a novel family of triazine-based inhibitors of sorbitol dehydrogenase with oral activity: 1-?4-[3R,5S-dimethyl-4-(4-methyl-[1,3,5]triazin-2-yl)-piperazin-1-yl]-[1,3,5]triazin-2-yl?-(R) ethanol

  摘要：

  Two new templates, (R) 2-hydroxyethyl-pyridine and (R) 2-hydroxyethyl-triazine, were used to design novel sorbitol dehydrogenase inhibitors (SDIs). The design concept included spawning of these templates to function as effective ligands to the catalytic zinc within the enzyme through incorporation of optimally substituted piperazino-triazine side chains so as to accommodate the active site in the enzyme for efficient binding. This strategy resulted in orally active SDIs, which penetrate key tissues, for example, sciatic nerve of chronically diabetic rats. The latter template led to the design of the title inhibitor, 33, which normalized the elevated sciatic nerve fructose by 96% at an oral dose of 10 mg/kg. (C) 2003 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/s0968-0896(03)00490-5
• 作为产物：
  描述：

  2-hydroxymethyl-4-[4'-(N,N-dimethylsulfamoyl)piperazin-1-yl]pyridine 在 manganese(IV) oxide 作用下， 以 四氢呋喃 、 乙醚 、 氯仿 为溶剂， 反应 4.5h， 生成 4-[2-(1-羟基-乙基)-吡啶-4-基]-哌嗪-1-磺酸二甲基酰胺
  参考文献：
  名称：

  Design and synthesis of a novel family of triazine-based inhibitors of sorbitol dehydrogenase with oral activity: 1-?4-[3R,5S-dimethyl-4-(4-methyl-[1,3,5]triazin-2-yl)-piperazin-1-yl]-[1,3,5]triazin-2-yl?-(R) ethanol

  摘要：

  Two new templates, (R) 2-hydroxyethyl-pyridine and (R) 2-hydroxyethyl-triazine, were used to design novel sorbitol dehydrogenase inhibitors (SDIs). The design concept included spawning of these templates to function as effective ligands to the catalytic zinc within the enzyme through incorporation of optimally substituted piperazino-triazine side chains so as to accommodate the active site in the enzyme for efficient binding. This strategy resulted in orally active SDIs, which penetrate key tissues, for example, sciatic nerve of chronically diabetic rats. The latter template led to the design of the title inhibitor, 33, which normalized the elevated sciatic nerve fructose by 96% at an oral dose of 10 mg/kg. (C) 2003 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/s0968-0896(03)00490-5